Literature DB >> 16771858

Critical role of M. tuberculosis for dendritic cell maturation to induce collagen-induced arthritis in H-2b background of C57BL/6 mice.

Hirayasu Kai1, Kazuko Shibuya, Yinan Wang, Hirotaka Kameta, Tomie Kameyama, Satoko Tahara-Hanaoka, Akitomo Miyamoto, Shin-ichiro Honda, Isao Matsumoto, Akio Koyama, Takayuki Sumida, Akira Shibuya.   

Abstract

Collagen-induced arthritis (CIA) can be induced even in CIA-resistant H-2(b) background of C57BL/6 mice when these mice are immunized with type II collagen (CII) emulsified in complete Freund's adjuvant (CFA) containing high, but not low, dose of Mycobacterium tuberculosis. Here, we investigated the pathogenesis of CIA in C57BL/6 mice induced by the immunizing protocol. We examined expressions of cytokines, costimulatory molecules and major histocompatibility complex (MHC) class II in draining lymph nodes (DLN) in CIA-induced C57BL/6 mice by quantitative reverse transcription-polymerase chain reaction. We also examined an effect of M. tuberculosis on the expression of these molecules on dendritic cells (DC) in vitro by flow cytometry. We finally examined an effect of M. tuberculosis in CFA used for immunization with CII antigen on priming of CD4+ helper T cells specific to CII in DLN of CIA-induced C57BL/6 mice. The expression of interferon-gamma (IFN-gamma), Interleukin-12p40 (IL-12p40), costimulatory molecules CD40, CD80 and CD86 and MHC class II were up-regulated in DLN of CIA-induced C57BL/6 mice. Expressions of these costimulatory molecules were also up-regulated on DC after stimulation with high, but not low, dose of M. tuberculosis in vitro. Furthermore, priming of CD4+ helper T cells specific to CII antigen in DLN required immunization with CII using CFA containing high, but not low, dose of M. tuberculosis. These results suggested that high dose of M. tuberculosis were required for maturation of DC enough to prime CD4+ helper T cells specific to CII antigen in DLN of H-2b background of C57BL/6 mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771858      PMCID: PMC1782291          DOI: 10.1111/j.1365-2567.2006.02361.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

Review 1.  The molecular basis of T helper 1 and T helper 2 cell differentiation.

Authors:  A O'Garra; N Arai
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

2.  IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide.

Authors:  D O Willenborg; S A Fordham; M A Staykova; I A Ramshaw; W B Cowden
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

3.  Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis.

Authors:  S H Park; D J Min; M L Cho; W U Kim; J Youn; W Park; C S Cho; H Y Kim
Journal:  Arthritis Rheum       Date:  2001-03

4.  Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis.

Authors:  I K Campbell; J A Hamilton; I P Wicks
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

5.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

6.  Susceptibility to collagen-induced arthritis: cytokine-mediated regulation.

Authors:  R A Ortmann; E M Shevach
Journal:  Clin Immunol       Date:  2001-01       Impact factor: 3.969

7.  Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis.

Authors:  B P Leung; I B McInnes; E Esfandiari; X Q Wei; F Y Liew
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

8.  Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10.

Authors:  S Thoma-Uszynski; S M Kiertscher; M T Ochoa; D A Bouis; M V Norgard; K Miyake; P J Godowski; M D Roth; R L Modlin
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

9.  Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis.

Authors:  Y Morita; M Yamamura; M Kawashima; S Harada; K Tsuji; K Shibuya; K Maruyama; H Makino
Journal:  Arthritis Rheum       Date:  1998-09

10.  Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis.

Authors:  C Q Chu; S Wittmer; D K Dalton
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  12 in total

1.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

2.  IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

Authors:  Irina Kochetkova; Sarah Golden; Kathryn Holderness; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

3.  Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses.

Authors:  Qiaoxia Li; Bin Cong; Baoen Shan; Jingge Zhang; Haiying Chen; Tao Wang; Chunling Ma; Jin Qin; Di Wen; Feng Yu
Journal:  Rheumatol Int       Date:  2010-04-08       Impact factor: 2.631

4.  Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

Authors:  Christine Huang; Ming Zheng; Zheng Yang; A David Rodrigues; Punit Marathe
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

5.  Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.

Authors:  M Ikić Matijašević; D Flegar; N Kovačić; V Katavić; T Kelava; A Šućur; S Ivčević; H Cvija; E Lazić Mosler; I Kalajzić; A Marušić; D Grčević
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

6.  Inhibition of fucosylation reshapes inflammatory macrophages and suppresses type II collagen-induced arthritis.

Authors:  Jun Li; Hui-Chen Hsu; Yana Ding; Hao Li; Qi Wu; PingAr Yang; Bao Luo; Amber L Rowse; David M Spalding; S Louis Bridges; John D Mountz
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

7.  Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models.

Authors:  Muriel Elhai; Gilles Chiocchia; Carmen Marchiol; Franck Lager; Gilles Renault; Marco Colonna; Guenter Bernhardt; Yannick Allanore; Jérôme Avouac
Journal:  J Inflamm (Lond)       Date:  2015-02-08       Impact factor: 4.981

8.  Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen.

Authors:  Julia J Inglis; Gabriel Criado; Mino Medghalchi; Melanie Andrews; Ann Sandison; Marc Feldmann; Richard O Williams
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

9.  T-cell immune adaptor SKAP1 regulates the induction of collagen-induced arthritis in mice.

Authors:  Xin Smith; Alison Taylor; Christopher E Rudd
Journal:  Immunol Lett       Date:  2016-05-12       Impact factor: 3.685

Review 10.  Infections and autoimmunity: a panorama.

Authors:  V Pordeus; M Szyper-Kravitz; R A Levy; N M Vaz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.